Galera Therapeutics, Inc. (GRTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F ...

The average one-year price target for Galera Therapeutics (NASDAQ:GRTX) has been revised to 0.38 / share. This is an increase of 7.14% from the prior estimate of 0.36 dated October 31, 2023. The price ...

Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...

Galera Therapeutics (NASDAQ: GRTX) stock implied 80% and change. GRTX stock plunged because the Food and Drug Administration, the FDA, refused authorisation for the company’s treatment for radiation ...

Galera Therapeutics (NASDAQ:GRTX) stock is rocketing higher Thursday morning after providing an update on its pancreatic cancer clinical trial. Source: CI Photos / Shutterstock.com Galera Therapeutics ...

Galera Therapeutics (NASDAQ: GRTX) stock is up 22% premarket this morning. GRTX stock is up on the announcement that there is to be a meeting with the FDA. The FDA is, as with all development pharma ...

Shares of Galera Therapeutics, Inc. GRTX were down almost 70% on Tuesday after the company announced unsatisfactory data from the phase III ROMAN study evaluating avasopasem for treating severe oral ...

Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically ...

The FDA issued a Complete Response Letter (CRL) to Galera Therapeutics Inc's GRTX New Drug Application (NDA) for avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis (SOM) ...